You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆汇港股聚焦(9.17)︱深高速获招商公路举牌;君实生物产品获得FDA孤儿药资格认定
格隆汇 09-17 23:11

【财务数据】

光汇石油(00933.HK)17/18财年中期盈转亏至8500万港元

中油港燃(08132.HK)19/20财年前三季度亏损收窄至2304.6万港元

【业绩预告】

中国高精密(00591.HK)预计年度亏损扩大至8600万-9000万元

新维国际控股(08086.HK)料年度除税后亏损大幅增加不少于70%

【运营数据】

北控清洁能源集团(01250.HK)前8月累计总发电量同比增长约4.6%

诉讼处罚】

招商证券(06099.HK):仲裁庭裁决林某向招商资管偿付融资本金4.09亿元

首都信息(01075.HK):法院驳回厦门锐泰隆的上诉

【股本重组】

金卫医疗(00801.HK)股份买卖单位改为每手80万股

并购出售】

正商实业(00185.HK)斥6135.4万元收购新乡市一幅地块

上实城市开发(00563.HK)附属以4.29亿元竞得上海闵行区土地

中国铁塔(00788.HK):中国国新拟挂牌转让出售达沃启航不超50%股权

复星医药(02196.HK)拟450万元收购易研云(上海)医疗科技全部股权

【增发供股】

泰锦控股(08321.HK)拟折让13.22%配售3200万股 筹资330万港元

重大事项

深圳高速公路股份(00548.HK)获股东招商公路增持A股约217.72万股及H股1965万股

民信国际控股(08456.HK)股价异常波动 前控股股东陆秀娟悉数出售所持公司股权

ESR(01821.HK)股东拟配售股份

复星医药(02196.HK):深圳复星健康注册资本增至约1.2亿元

君实生物(01877.HK):产品“特瑞普利单抗”获得FDA孤儿药资格认定

石药集团(01093.HK)注射用多西他赛(白蛋白结合型)获美国临床试验批件

红星美凯龙(01528.HK)拟开展商业物业资产证券化业务

复星医药(02196.HK):天津星魅获Raziel许可在中国独家临床开发和商业化RZL012

复宏汉霖-B(02696.HK):HLX02与原研曲妥珠单抗在HER2阳性转移性乳腺癌患者上的疗效、安全性和药代动力学相当

大唐新能源(01798.HK)实现装机容量突破千万千瓦

NEXION TECH(08420.HK)与XOX Bhd订立临时技术合伙协议

【回购注销】

中国旺旺(00151.HK)9月17日耗资4817.05万港元回购902.2万股

中国燃气(00384.HK)9月17日耗资2554.55万港元回购121.84万股

金鹰商贸集团(03308.HK)9月17日耗资310.48万港元回购44万股

雷蛇(01337.HK)9月17日耗资340万港元回购200万股

齐屹科技(01739.HK)9月17日耗资247.33万港元回购113.3万股

数码通电讯(00315.HK)9月17日耗资206.9万港元回购49.15万股

富智康集团(02038.HK)9月17日耗资138.2万港元回购140.2万股

维信金科(02003.HK)9月17日耗资44万港元回购10.6万股

叶氏化工集团(00408.HK)9月17日耗资108.56万港元回购42.8万股

中国水务(00855.HK)9月17日耗资126万港元回购20.6万股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account